

Javier De La Serna

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9050167/javier-de-la-serna-publications-by-year.pdf>
Version: 2024-04-04

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

93 papers	4,894 citations	29 h-index	69 g-index
102 ext. papers	5,638 ext. citations	4.3 avg, IF	4.4 L-index

#	Paper	IF	Citations
93	Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in the Real -World Setting in Spain: The Venares Study. <i>Blood</i> , 2021 , 138, 1561-1561	2.2	
92	Different Prognostic Impact of Recurrent Gene Mutations in IGHV-Mutated and IGHV-Unmutated Chronic Lymphocytic Leukemia: A Retrospective, Multi-Center Cohort Study By Eric, the European Research Initiative on CLL, in Harmony. <i>Blood</i> , 2021 , 138, 2617-2617	2.2	
91	B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with lenalidomide. <i>Blood</i> , 2021 , 137, 2267-2271	2.2	3
90	Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM). <i>PLoS ONE</i> , 2021 , 16, e0257353	3.7	
89	ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2849-2861	2.2	131
88	Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study. <i>Leukemia</i> , 2020 , 34, 2333-2341	10.7	13
87	Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx). <i>Blood</i> , 2020 , 136, 19-21	2.2	19
86	Efficacy of Subsequent Novel Targeted Therapies, Including Repeated Venetoclax-Rituximab (VenR), in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Previously Treated with Fixed-Duration Venr in the Murano Study. <i>Blood</i> , 2020 , 136, 44-45	2.2	7
85	Acalabrutinib (Acala) versus idelalisib plus rituximab (IdR) or bendamustine plus rituximab (BR) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): ASCEND final results.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 8015-8015	2.2	4
84	Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols. <i>European Journal of Haematology</i> , 2020 , 104, 162-169	3.8	2
83	Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4042-4054	2.2	66
82	Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. <i>Cancer Medicine</i> , 2020 , 9, 8468-8479	4.8	8
81	Real life outcomes of patients aged ≥5 years old with acute promyelocytic leukemia: experience of the PETHEMA registry. <i>Leukemia and Lymphoma</i> , 2019 , 60, 2720-2732	1.9	2
80	Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. <i>Lancet Infectious Diseases</i> , 2019 , 19, 988-1000	25.5	82
79	Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 322, 123-133	27.4	80
78	Four-Year Analysis of Murano Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab (VenR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2019 , 134, 355-355	2.2	13
77	Preliminary Results of Ibrutinib Followed By Ofatumumab Consolidation in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): GELL7 Trials from the Spanish Group of CLL (GELL7C). <i>Blood</i> , 2019 , 134, 4296-4296	2.2	0

76	Safety and Efficacy of Autologous Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients - the Diadem Study from the Chronic Malignancies Working Party of the EBMT. <i>Blood</i> , 2019 , 134, 4574-4574	2.2	1
75	Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy. <i>Leukemia and Lymphoma</i> , 2019 , 60, 1146-1155	1.9	4
74	An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens. <i>Leukemia and Lymphoma</i> , 2019 , 60, 1030-1035	1.9	7
73	Autoimmune hemolytic anemia (AIHA) following allogeneic hematopoietic stem cell transplantation (HSCT): A retrospective analysis and a proposal of treatment on behalf of the Grupo Español De Trasplante de Medula Osea en Niños (GETMON) and the Grupo Español de Trasplante Hematológico (GETH). <i>Transfusion Medicine Reviews</i> , 2019 , 33, 170-176	7.4	19
72	Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. <i>Haematologica</i> , 2018 , 103, 1209-1217	6.6	24
71	Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2018 , 378, 1107-1120	59.2	455
70	Twelve years of experience with miglustat in the treatment of type 1 Gaucher disease: The Spanish ZAGAL project. <i>Blood Cells, Molecules, and Diseases</i> , 2018 , 68, 173-179	2.1	15
69	Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project. <i>Cytometry Part B - Clinical Cytometry</i> , 2018 , 94, 121-128	3.4	86
68	MURANO Trial Establishes Feasibility of Time-Limited Venetoclax-Rituximab (VenR) Combination Therapy in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2018 , 132, 184-184	2.2	7
67	A novel high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia. <i>Oncotarget</i> , 2018 , 9, 26019-26031	3.3	5
66	B-cell acute lymphoblastic leukemia (B-ALL) in CLL patients treated with lenalidomide.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 7531-7531	2.2	
65	Characteristics and Outcome of Older Patients with Acute Promyelocytic Leukemia Front-Line Treated with or without Arsenic Trioxide In International Collaborative Study. <i>Blood</i> , 2018 , 132, 80-80	2.2	
64	Tocilizumab to Prevent Infusion-Related Events in Patients with Chronic Lymphocytic Leukemia and Co-Morbidities Treated with Obinutuzumab and Chlorambucil: Results from the Randomized Phase Ib GALACTA Trial. <i>Blood</i> , 2018 , 132, 4419-4419	2.2	
63	Venetoclax Plus Rituximab Is Superior to Bendamustine Plus Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia - Results from Pre-Planned Interim Analysis of the Randomized Phase 3 Murano Study. <i>Blood</i> , 2017 , 130, LBA-2-LBA-2	2.2	12
62	Patients with type 1 Gaucher disease in Spain: A cross-sectional evaluation of health status. <i>Blood Cells, Molecules, and Diseases</i> , 2016 , 56, 23-30	2.1	21
61	Updated Analysis of Overall Survival in Randomized Phase III Study of Idelalisib in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL. <i>Blood</i> , 2016 , 128, 231-231	2.2	4
60	Results of a randomized, double-blind placebo-controlled phase 3 study evaluating idelalisib in combination with bendamustine and rituximab in patients with relapsed/refractory CLL and adverse prognostic features.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 7514-7514	2.2	
59	All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies. <i>Annals of Hematology</i> , 2015 , 94, 1347-56	3	24

58	Outcome of graft failure after allogeneic stem cell transplant: study of 89 patients. <i>Leukemia and Lymphoma</i> , 2015 , 56, 656-62	1.9	22
57	Reproducible Diagnosis of Chronic Lymphocytic Leukemia (CLL) By Flow Cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation Project. <i>Blood</i> , 2015 , 126, 4146-4146	2.2	2
56	An Innovative High-Throughput Ex Vivo Drug Assay Incorporating the Native Microenvironment Reveals a Novel Mechanism of Action of Idelalisib in CLL. <i>Blood</i> , 2015 , 126, 2485-2485	2.2	
55	Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. <i>New England Journal of Medicine</i> , 2014 , 370, 1101-10	59.2	1048
54	Prognostic Value of Chromosome 1 Abnormalities in Myelodysplastic Syndrome. <i>Blood</i> , 2014 , 124, 3240-3240		
53	Characterization and prognostic implication of 17 chromosome abnormalities in myelodysplastic syndrome. <i>Leukemia Research</i> , 2013 , 37, 769-76	2.7	8
52	Complex, not monosomal, karyotype is the cytogenetic marker of poorest prognosis in patients with primary myelodysplastic syndrome. <i>Journal of Clinical Oncology</i> , 2013 , 31, 916-22	2.2	60
51	Substrate Reduction Therapy With Miglustat In Type 1 Gaucher Disease In Spain. Nine Years Outcomes Update On ZAGAL Study. <i>Blood</i> , 2013 , 122, 4713-4713	2.2	4
50	Effects Of Bendamustine Plus Rituximab On The Distribution Of Normal Peripheral Blood Leucocyte Populations In Advanced-Stage Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2013 , 122, 5289-5289	2.2	1
49	Head-To-Head Comparison Of Obinutuzumab (GA101) Plus Chlorambucil (Clb) Versus Rituximab Plus Clb In Patients With Chronic Lymphocytic Leukemia (CLL) and Co-Existing Medical Conditions (Comorbidities): Final Stage 2 Results Of The CLL11 Trial. <i>Blood</i> , 2013 , 122, 6-6	2.2	12
48	Prospective, Observational Study To Assess The Safety Of Rituximab In Combination With Chemotherapy In Patients With Previously-Untreated Or Relapsed Or Refractory B Cell-Lineage Chronic Lymphocytic Leukaemia (B-CLL): Preliminary Results. <i>Blood</i> , 2013 , 122, 5310-5310	2.2	
47	Chronic lymphocytic leukaemia with 17p deletion: a retrospective analysis of prognostic factors and therapy results. <i>British Journal of Haematology</i> , 2012 , 157, 67-74	4.5	36
46	Assessment of Minimal Residual Disease Levels in B-CLL After Front-Line Treatment with FC-R and Rituximab Maintenance. <i>Blood</i> , 2012 , 120, 4599-4599	2.2	
45	Evaluation of Spanish Gaucher disease patients after a 6-month imiglucerase shortage. <i>Blood Cells, Molecules, and Diseases</i> , 2011 , 46, 115-8	2.1	25
44	Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. <i>Blood</i> , 2011 , 117, 1799-805	2.2	95
43	Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: analysis of the Spanish Compassionate Use Registry in advanced patients. <i>International Journal of Hematology</i> , 2011 , 93, 351-360	2.3	18
42	Relationship between deoxycytidine kinase (DCK) genotypic variants and fludarabine toxicity in patients with follicular lymphoma. <i>Leukemia Research</i> , 2011 , 35, 431-7	2.7	3
41	Frontline treatment of follicular lymphoma with fludarabine, cyclophosphamide, and rituximab followed by rituximab maintenance: toxicities overcome its high antilymphoma effect. Results from a Spanish Cooperative Trial (LNHF-03). <i>Leukemia and Lymphoma</i> , 2011 , 52, 409-16	1.9	8

40	Long-Term Results of Fludarabine/Melphalan as a Reduced-Intensity Conditioning Regimen in Mantle Cell Lymphoma: The GELTAMO Experience. <i>Therapeutic Advances in Hematology</i> , 2011 , 2, 5-10	5.7	11
39	Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab. <i>Expert Review of Hematology</i> , 2011 , 4, 9-16	2.8	10
38	Prognostic Impact of Monosomal Karyotype in Patients with Myelodysplastic Syndrome and Abnormal Karyotype. A Report From the Spanish Group of MDS (GESMD). <i>Blood</i> , 2011 , 118, 1724-1724	2.2	2
37	Graft-Failure After Allogeneic Stem Cell Transplantation. Outcome and Prognostic Factors in 80 Patients. <i>Blood</i> , 2011 , 118, 1936-1936	2.2	
36	Myeloablative Conditioning with Intravenous Busulfan In One Daily Dose and Fludarabine (BUF) for HLA-Identical Sibling Allogeneic HSCT In Myeloid Malignancies. <i>Blood</i> , 2011 , 118, 3010-3010	2.2	
35	Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic Acid and anthracycline-based chemotherapy. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3872-9	2.2	59
34	Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials. <i>Haematologica</i> , 2010 , 95, 1176-82	6.6	61
33	Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. <i>Blood</i> , 2010 , 115, 5137-46	2.2	234
32	Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group. <i>Blood</i> , 2010 , 116, 5650-9	2.2	29
31	Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. <i>Haematologica</i> , 2010 , 95, 424-31	6.6	72
30	Rituximab Maintenance Treatment After Combined Fludarabine, Cyclophosphamide and Rituximab In Previously Untreated Patients with Progressive B-Cell Chronic Lymphocytic Leukemia (CLL): Interim Analysis of An Ongoing Phase II Multicenter Trial On Behalf of the Spanish CLL Study Group (GELLC). <i>Blood</i> , 2010 , 116, 2448-2448	2.2	
29	Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide. <i>Leukemia and Lymphoma</i> , 2009 , 50, 1283-9	1.9	5
28	Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis. <i>Haematologica</i> , 2009 , 94, 1242-9	6.6	78
27	Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. <i>Blood</i> , 2009 , 113, 775-83	2.2	232
26	Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. <i>Blood</i> , 2008 , 111, 1078-84	2.2	135
25	Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. <i>Blood</i> , 2008 , 111, 3395-402	2.2	258
24	Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group. <i>Blood</i> , 2008 , 112, 3130-4	2.2	129
23	Impact of ATRA Duration during the Induction Treatment of Newly Diagnosed APL. <i>Blood</i> , 2008 , 112, 139-139	2.2	2

22	Induction with Fludarabine, Cyclophosphamide and Rituximab as Front-Line Therapy Against Follicular Lymphoma: Results from a Cooperative Spanish Trial. <i>Blood</i> , 2007 , 110, 1286-1286	2.2	1
21	Risk-Adapted Treatment of Acute Promyelocytic Leukemia: Updated Results of the Spanish PETHEMA LPA99 Trial Using ATRA and Anthracycline Monochemotherapy.. <i>Blood</i> , 2007 , 110, 590-590	2.2	1
20	Long Term Results of Non-Myeloablative Stem Cell Transplantation in Non-Hodgkin's Lymphomas: FLU150/MEL80 (Madrid Protocol).. <i>Blood</i> , 2007 , 110, 5047-5047	2.2	
19	Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 172-83	4.7	119
18	Incidence and Risk Factors for Thrombosis in Patients with Acute Promyelocytic Leukemia. Experience of the PETHEMA LPA96 and LPA99 Protocols.. <i>Blood</i> , 2006 , 108, 1503-1503	2.2	13
17	Induction with Fludarabine, Cyclophosphamide and Rituximab Followed by Maintenance with Rituximab: Results of a Prospective Study in 75 Patients (LNHF-03).. <i>Blood</i> , 2006 , 108, 2762-2762	2.2	3
16	Long Remission Are Possible after Non Myeloablative Transplant in Patients with Follicular Non-Hodgkin's Lymphoma (NHL): Results of Two Prospectives Multicenter Trials.. <i>Blood</i> , 2006 , 108, 3024-3024	2.2	3
15	Retinoic Acid Syndrome in Patients with Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid and Anthracycline Monochemotherapy.. <i>Blood</i> , 2006 , 108, 2010-2010	2.2	
14	A modified cord blood collection method achieves sufficient cell levels for transplantation in most adult patients. <i>Stem Cells</i> , 2005 , 23, 324-34	5.8	53
13	Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA Group. <i>Journal of Clinical Oncology</i> , 2005 , 23, 7632-40	2.2	111
12	Discrepancy between Phenotype and Genotype for Factor V Leiden Mutation in Recipients of Liver Transplant.. <i>Blood</i> , 2005 , 106, 4120-4120	2.2	
11	Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. <i>Blood</i> , 2004 , 103, 1237-43	2.2	338
10	All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia. <i>Blood</i> , 2004 , 104, 3490-3	2.2	85
9	Kaposi's sarcoma after allogeneic peripheral blood stem cell transplantation. <i>International Journal of Dermatology</i> , 2003 , 42, 647-9	1.7	11
8	Tandem transplants with different high-dose regimens improve the complete remission rates in multiple myeloma. Results of a Grupo Español de Síndromes Linfoproliferativos/Trasplante Autólogo de Médula Ósea phase II trial. <i>British Journal of Haematology</i> , 2003 , 120, 296-303	4.5	27
7	Analysis of factors associated with low peripheral blood progenitor cell collection in normal donors. <i>Transfusion</i> , 2002 , 42, 4-9	2.9	77
6	Second mobilization and collection of peripheral blood progenitor cells in healthy donors is associated with lower CD34(+) cell yields. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2002 , 11, 705-9		15
5	Myeloablative treatments for multiple myeloma: update of a comparative study of different regimens used in patients from the Spanish registry for transplantation in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2002 , 43, 67-74	1.9	41

4	Favourable effect of the combination of acute and chronic graft-versus-host disease on the outcome of allogeneic peripheral blood stem cell transplantation for advanced haematological malignancies. <i>British Journal of Haematology</i> , 2001 , 114, 544-50	4.5	20
3	Donor age-related differences in PBPC mobilization with rHuG-CSF. <i>Transfusion</i> , 2001 , 41, 201-5	2.9	45
2	Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple Myeloma. <i>British Journal of Haematology</i> , 2000 , 109, 138-47	4.5	61
1	Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. <i>British Journal of Haematology</i> , 2000 , 109, 438-46	4.5	87